argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia
The study did not meet the primary endpoint of a sustained platelet count response in chronic ITP patients.
- The study did not meet the primary endpoint of a sustained platelet count response in chronic ITP patients.
- Additional analyses of the dataset are ongoing and the full results will be presented at an upcoming medical meeting and in a peer-reviewed publication.
- “We are very grateful to everyone involved in the ADVANCE-SC study, especially the patients and their families, the investigators, and our internal team who worked tirelessly to complete this global study.
- A webcast of the live call and replay may be accessed on the Investors section of the argenx website.